Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation Herbert Pichler, Karolina Horner, Gernot Engstler, Ulrike Poetschger, Evgenia Glogova, Susanne Karlhuber, Manuel Martin, Werner Eibler, Volker Witt, Wolfgang Holter, Susanne Matthes-Martin Biology of Blood and Marrow Transplantation Volume 23, Issue 7, Pages 1128-1133 (July 2017) DOI: 10.1016/j.bbmt.2017.03.022 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Five-year overall survival (OS) estimates (A) and 2-year cumulative incidences (CI) of transplantation-related mortality (TRM) (B) for patients with and without VOD surviving beyond day +26 after transplantation. Biology of Blood and Marrow Transplantation 2017 23, 1128-1133DOI: (10.1016/j.bbmt.2017.03.022) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions